Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SPPI Spectrum Pharmaceuticals (SPPI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Spectrum Pharmaceuticals Stock (NASDAQ:SPPI) 30 days 90 days 365 days Advanced Chart Ad DTI$20k in extra income? My friend Alex Reid just might have created my favorite strategy right now. You see, Alex has figured out how to cut-the-corner so to speak, and be one of the laziest traders possible…. While still showing his traders how to target big money. This past year, his LIVE “lazy trade” alerts have delivered impressive results—and that’s only a fraction of the opportunities he’s shared. And that’s just just a quarter of the total trade alerts he’s sent out. The true total profit potential his beta-testers have had the chance to target is far larger than $20k. Alex recorded a special video training where he reveals exactly how much. Get SPPI alerts:Sign Up Key Stats Today's Range$1.03▼$1.0350-Day Range$0.94▼$1.0352-Week Range$0.32▼$1.57VolumeN/AAverage Volume1.93 million shsMarket Capitalization$211.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.Read More… Receive SPPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SPPI Stock News HeadlinesNon-Hodgkin’s Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and BarriersNovember 4, 2024 | theglobeandmail.comQylur Awarded SBIR Phase II Contract for a Tactical AI Spectrum Classifier Systems (TASCS)October 2, 2024 | globenewswire.com$20k in extra income? My friend Alex Reid just might have created my favorite strategy right now. You see, Alex has figured out how to cut-the-corner so to speak, and be one of the laziest traders possible…. While still showing his traders how to target big money. This past year, his LIVE “lazy trade” alerts have delivered impressive results—and that’s only a fraction of the opportunities he’s shared. And that’s just just a quarter of the total trade alerts he’s sent out. The true total profit potential his beta-testers have had the chance to target is far larger than $20k. December 26, 2024 | DTI (Ad)NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387August 19, 2024 | proactiveinvestors.comSTALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in BiomedicinesJune 27, 2024 | globenewswire.comOsivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033June 25, 2024 | businesswire.comPneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 ConferenceMay 23, 2024 | globenewswire.comPneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024May 2, 2024 | globenewswire.comSee More Headlines SPPI Stock Analysis - Frequently Asked Questions How were Spectrum Pharmaceuticals' earnings last quarter? Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) released its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.07. What other stocks do shareholders of Spectrum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spectrum Pharmaceuticals investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Toast (TOST), Ginkgo Bioworks (DNA) and NOVONIX (NVNXF). Company Calendar Last Earnings11/10/2021Today12/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:SPPI CUSIP84763A10 CIK831547 Webwww.sppirx.com Phone(617) 586-3900Fax702-260-7405Employees86Year Founded2002Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,400,000.00 Net MarginsN/A Pretax Margin-263.04% Return on Equity-218.44% Return on Assets-66.16% Debt Debt-to-Equity RatioN/A Current Ratio2.71 Quick Ratio2.38 Sales & Book Value Annual Sales$10.11 million Price / Sales20.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book6.87Miscellaneous Outstanding Shares205,250,000Free Float199,704,000Market Cap$211.41 million OptionableOptionable Beta2.15 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:SPPI) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spectrum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spectrum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
